Split History
ETFs Holding KBIO »    KBIO Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Kalobios Pharmaceuticals is a biopharmaceutical company focused on the development of monoclonal antibody therapeutics. Using Co.'s Humaneered® antibody technology, Co. has produced a portfolio of antibodies to treat medical conditions with a primary clinical focus on respiratory diseases and cancer. Co. has developed three monoclonal antibodies to the clinical development stage: KB004, which is a Humaneered® anti-EphA3 monoclonal antibody; KB003, which is a Humaneered® anti-granulocyte macrophage colony-stimulating factor monoclonal antibody; and KB001-A, which is a Humaneered® developed for the prevention and treatment of Pseudomonas aeruginosa infections. According to our KBIO split history records, KBIO has had 1 split.
KBIO split history picture
KBIO (KBIO) has 1 split in our KBIO split history database. The split for KBIO took place on July 14, 2015. This was a 1 for 8 reverse split, meaning for each 8 shares of KBIO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 125 share position following the split.

When a company such as KBIO conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the KBIO split history from start to finish, an original position size of 1000 shares would have turned into 125 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into KBIO shares, starting with a $10,000 purchase of KBIO, presented on a split-history-adjusted basis factoring in the complete KBIO split history. KBIO split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 01/31/2013
End date: 08/04/2017
Start price/share: $64.00
End price/share: $2.19
Dividends collected/share: $0.00
Total return: -96.58%
Average Annual Total Return: -52.71%
Starting investment: $10,000.00
Ending investment: $342.16
Years: 4.51
Date Ratio
07/14/20151 for 8
KBIO is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

KIDS Split History
KOOL Split History
LCAV Split History
LCI Split History
LH Split History
LIFE Split History
LJPC Split History
LLY Split History
LPTN Split History
LUX Split History

Xenetic Biosciences, Inc. (XBIO)
Yuma Energy, Inc. (YUMA)
Avinger, Inc. (AVGR)
Sonoma Pharmaceuticals, Inc. (SOMA)
Hudson Global, Inc. (HSON)
Jaguar Health, Inc. (JAGX)
Cesca Therapeutics Inc. (KOOL)
Northern Technologies International Corporation (NTIC)
Digirad Corporation (DRAD)
Hemispherx Biopharma, Inc. (HEB)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

KBIO Insider Buying

KBIO Split History | www.SplitHistory.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.